Завод ДИОД DIOD

Завод ДИОД Income Statement 2007-2025 | DIOD

Annual Income Statement Завод ДИОД

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	549 M	561 M	602 M	517 M	658 M	774 M	825 M	886 M	964 M	1.28 B	1.14 B	1.15 B	1.55 B	1.55 B	1.56 B	1.73 B	1.62 B
Cost Of Revenue	255 M	242 M	245 M	192 M	300 M	329 M	411 M	485 M	316 M	583 M	400 M	460 M	711 M	752 M	726 M	674 M	677 M
Gross Profit	294 M	319 M	357 M	325 M	358 M	446 M	414 M	401 M	649 M	700 M	737 M	691 M	839 M	796 M	833 M	1.06 B	947 M
Gross Profit Ratio	0.54	0.57	0.59	0.63	0.54	0.58	0.5	0.45	0.67	0.55	0.65	0.6	0.54	0.51	0.53	0.61	0.58
General and Administrative Expenses	162 M	29.8 M	23.2 M	19.7 M	27.3 M	136 M	37.4 M	50.7 M	28.2 M	23.8 M	164 M	27.4 M	156 M	150 M	160 M	154 M	-
Selling And Marketing Expenses	122 M	68.6 M	96.7 M	97.5 M	125 M	195 M	262 M	122 M	336 M	286 M	390 M	286 M	383 M	332 M	369 M	516 M	-
Selling General And Administrative Expenses	293 M	98.3 M	120 M	117 M	153 M	371 M	300 M	173 M	364 M	310 M	553 M	314 M	539 M	482 M	529 M	670 M	538 M
Other Expenses	-690 K	175 M	141 M	132 M	134 M	18.2 M	-37.3 M	4.17 M	-24.6 M	193 M	-207 M	-11 M	-52.5 M	-46.8 M	-236 M	-88.5 M	57.8 M
Operating Expenses	292 M	274 M	261 M	249 M	286 M	389 M	467 M	362 M	572 M	517 M	554 M	533 M	549 M	493 M	310 M	599 M	614 M
Cost And Expenses	547 M	516 M	507 M	441 M	586 M	718 M	879 M	847 M	888 M	1.1 B	954 M	992 M	1.26 B	1.25 B	1.04 B	1.27 B	-1.29 B
Interest Expense	-	37 K	19 K	576 K	3.52 M	-	23.5 M	37.2 M	112 M	94.4 M	99.8 M	97.9 M	89.6 M	93.6 M	116 M	44.1 M	2.02 M
Depreciation And Amortization	20.6 M	5.24 M	15.9 M	18.5 M	18.1 M	29.9 M	26.5 M	28.6 M	6.54 M	9.73 M	-206 M	4.6 M	-51.1 M	-44 M	2.2 M	-4.54 M	20.5 M
EBITDA	22.4 M	65.2 M	131 M	77.2 M	109 M	90.4 M	35.7 M	-66.2 M	12.6 M	185 M	6.28 M	151 M	251 M	259 M	570 M	452 M	357 M
EBITDA Ratio	0.04	0.12	0.2	0.16	0.16	0.12	-0.08	-0.01	-0.17	0.14	-0.02	0.13	0.15	0.17	0.34	0.26	0.22
Operating Income	1.82 M	45.2 M	107 M	73.2 M	99.2 M	56.4 M	-46.5 M	49.5 M	91.9 M	184 M	183 M	163 M	291 M	303 M	523 M	457 M	333 M
Operating Income Ratio	0.0	0.08	0.18	0.14	0.15	0.07	-0.06	0.06	0.1	0.14	0.16	0.14	0.19	0.2	0.34	0.26	0.21
Income Before Tax	13.4 M	60 M	115 M	57.1 M	80.8 M	46.7 M	-26.9 M	-134 M	-106 M	81.1 M	-137 M	25.1 M	150 M	165 M	410 M	408 M	335 M
Income Before Tax Ratio	0.02	0.11	0.19	0.11	0.12	60.4	-0.03	-0.15	-0.11	0.06	-0.12	0.02	0.1	0.11	0.26	0.24	0.21
Income Tax Expense	4.98 M	17.6 M	26.1 M	22.3 M	15.5 M	36.5 M	-10.6 M	6.88 M	13.3 M	22.8 M	20.2 M	17.2 M	37.8 M	35.4 M	45.8 M	106 M	101 M
Net Income Ratio	0.02	0.07	0.15	0.07	0.1	0.01	-0.03	-0.16	-0.12	0.04	-0.14	0.01	0.08	0.11	0.24	0.17	0.14
Earnings Per Share, EPS	0.09	0.44	0.99	0.38	0.7	0.12	-0.29	-1.54	-1.31	0.63	-1.71	0.15	1.4	1.78	4.08	33.1 K	50 K
EPS Diluted	0.09	0.44	0.99	0.38	0.7	0.12	-0.29	-1.54	-1.31	0.63	-1.71	0.15	1.4	1.78	4.08	33.1 K	-
Weighted Average Shares Outstanding	91.5 M	91.5 M	91.5 M	98 M	92 M	91.5 M	90.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	9.15 K	9.15 K

All numbers in RUB currency

Quarterly Income Statement Завод ДИОД

	2023-Q2	2022-Q4	2022-Q2	2021-Q4	2021-Q2	2020-Q4	2020-Q2	2019-Q4	2019-Q2	2018-Q4	2018-Q2	2017-Q4	2017-Q2	2016-Q4	2016-Q2	2015-Q4	2015-Q2	2014-Q4	2014-Q2	2013-Q4	2013-Q2	2011-Q4	2011-Q2	2010-Q4	2010-Q2	2009-Q4	2009-Q2	2008-Q4	2008-Q2
Revenue	274 M	260 K	301 M	294 M	309 M	299 M	218 M	322 M	336 M	385 M	389 M	370 M	455 M	413 M	473 M	549 M	415 M	642 M	642 M	638 M	249 M	775 M	775 M	774 M	774 M	779 M	779 M	865 M	865 M
Cost Of Revenue	127 M	118 K	131 M	138 M	113 M	114 M	78.1 M	115 M	189 M	171 M	157 M	193 M	218 M	228 M	258 M	229 M	138 M	291 M	291 M	233 M	83.6 M	356 M	356 M	376 M	376 M	363 M	363 M	337 M	337 M
Gross Profit	147 M	142 K	171 M	156 M	195 M	185 M	140 M	206 M	147 M	214 M	232 M	177 M	237 M	185 M	215 M	320 M	278 M	350 M	350 M	405 M	166 M	420 M	420 M	398 M	398 M	417 M	417 M	528 M	528 M
Gross Profit Ratio	0.536	0.547	0.566	0.53	0.632	0.618	0.642	0.642	0.437	0.555	0.596	0.502	0.52	0.448	0.455	0.584	0.668	0.546	0.546	0.635	0.665	0.541	0.541	0.514	0.514	0.534	0.534	0.611	0.611
General and Administrative Expenses	81 M	70.6 K	43.8 K	-	-	63 M	57.3 M	-	-	64.6 M	71.5 M	-35.6 M	73 M	90.6 M	92.7 M	85.5 M	68.3 M	11.9 M	11.9 M	91.3 M	31.6 M	78.2 M	78.2 M	75 M	75 M	79.9 M	79.9 M	76.9 M	76.9 M
Selling And Marketing Expenses	61.1 M	33.1 K	32.6 K	-	-	60.8 M	67.8 M	-	-	92.7 M	103 M	149 M	113 M	96.8 M	55.2 M	173 M	198 M	143 M	143 M	238 M	68.8 M	192 M	192 M	166 M	166 M	184 M	184 M	258 M	258 M
Selling General And Administrative Expenses	146 M	111 K	153 M	140 M	121 M	127 M	127 M	174 M	124 M	190 M	181 M	108 M	192 M	189 M	167 M	406 M	283 M	155 M	155 M	344 M	106 M	270 M	270 M	241 M	241 M	264 M	264 M	335 M	335 M
Other Expenses	-345 K	-	488 K	826 K	662 K	18.6 M	4.4 M	-8.65 M	4.92 M	18.2 M	-	-58.1 M	20.8 M	6.22 M	-12.1 M	-177 M	-9.03 M	96.5 M	96.5 M	-31.2 M	13.9 M	-26.2 M	-26.2 M	-23.4 M	-23.4 M	-118 M	-118 M	-44.3 M	-44.3 M
Operating Expenses	146 M	115 K	152 M	139 M	120 M	146 M	131 M	183 M	119 M	208 M	181 M	255 M	213 M	196 M	155 M	230 M	276 M	258 M	258 M	313 M	121 M	274 M	274 M	247 M	247 M	155 M	155 M	300 M	300 M
Cost And Expenses	273 M	233 K	283 M	277 M	234 M	260 M	209 M	298 M	308 M	379 M	339 M	448 M	431 M	423 M	413 M	458 M	414 M	550 M	550 M	546 M	204 M	630 M	630 M	623 M	623 M	518 M	518 M	636 M	636 M
Interest Expense	-	-	-	569 K	424 K	-	-	424 M	2.39 B	-	-	23.5 M	-	-	-	-	-	47.2 M	47.2 M	-	-	44.8 M	44.8 M	46.8 M	46.8 M	57.9 M	57.9 M	22 M	22 M
Depreciation And Amortization	10.3 M	6.4 K	10.4 M	6.89 M	9.01 M	10.5 M	9.9 M	1.92 M	16.2 M	8.29 M	21.6 M	11.2 M	15.3 M	17.9 M	10.7 M	28.9 M	31.8 M	4.87 M	4.87 M	18.6 M	8.39 M	-25.6 M	-25.6 M	-22 M	-22 M	1.1 M	1.1 M	-2.27 M	-2.27 M
EBITDA	11.2 M	34.4 K	28.8 M	23.3 M	89.1 M	65.9 M	18.6 M	25.3 M	44 M	18.2 M	72.1 M	-24.3 M	60 M	13.4 M	58.8 M	-71.6 M	8.19 M	92.6 M	92.6 M	108 M	53.6 M	126 M	126 M	129 M	129 M	285 M	285 M	226 M	226 M
EBITDA Ratio	0.041	0.133	0.096	0.079	0.271	0.221	0.085	0.079	0.131	0.047	0.185	-0.079	0.132	0.032	0.124	-0.13	0.02	0.144	0.144	0.169	0.215	0.162	0.162	0.167	0.167	0.366	0.366	0.262	0.262
Operating Income	909 K	28 K	18.4 M	16.4 M	74.7 M	39.1 M	8.82 M	23.3 M	27.8 M	5.91 M	50.5 M	-70.4 M	23.9 M	-10.7 M	60.2 M	90.6 M	1.31 M	91.8 M	91.8 M	92.4 M	45.3 M	145 M	145 M	151 M	151 M	262 M	262 M	228 M	228 M
Operating Income Ratio	0.003	0.108	0.061	0.056	0.242	0.131	0.04	0.073	0.083	0.015	0.13	-0.056	0.053	-0.026	0.127	0.165	0.003	0.143	0.143	0.145	0.182	0.188	0.188	0.195	0.195	0.336	0.336	0.264	0.264
Income Before Tax	6.7 M	32.8 K	27.1 M	34.9 M	79.6 M	42 M	15.1 M	28.6 M	52.2 M	17.4 M	29.4 M	-65 M	38.2 M	-16 M	-118 M	-32.5 M	-73.6 M	40.6 M	40.6 M	21.4 M	-79.1 M	75 M	75 M	82.5 M	82.5 M	205 M	205 M	204 M	204 M
Income Before Tax Ratio	0.024	0.126	0.09	0.119	0.258	0.141	0.069	0.089	0.155	45.1	75.5	-0.033	0.084	-0.039	-0.25	-0.059	-0.177	0.063	0.063	0.034	-0.317	0.097	0.097	0.107	0.107	0.263	0.263	0.236	0.236
Income Tax Expense	2.49 M	7.44 K	10.2 M	8.79 M	17.3 M	15.5 M	6.78 M	20.6 M	-5.06 M	24.7 M	11.8 M	-14.3 M	3.68 M	19.1 M	-24.5 M	46.5 M	-66.4 M	11.4 M	11.4 M	10.5 M	4.87 M	18.9 M	18.9 M	17.7 M	17.7 M	22.9 M	22.9 M	52.9 M	52.9 M
Net Income Ratio	0.015	0.103	0.052	0.097	0.202	0.098	0.037	0.023	0.169	-0.024	0.052	-0.032	0.075	-0.083	-0.225	-0.144	-0.098	0.045	0.045	0.016	-0.335	0.082	0.082	0.105	0.105	0.24	0.24	0.175	0.175
Earnings Per Share, EPS	0.046	0.0	0.17	0.31	0.68	0.32	0.09	0.083	0.63	-0.1	0.22	-0.67	0.38	-0.38	-1.16	-0.86	-0.44	0.315	0.315	0.113	-0.91	0.7	0.7	0.89	0.89	2.04	2.04	16.5 K	16.5 K
EPS Diluted	0.046	0.0	0.17	0.31	0.68	0.32	0.09	0.083	0.63	-0.1	0.22	-0.67	0.38	-0.38	-1.16	-0.86	-0.44	0.315	0.315	0.113	-0.91	0.7	0.7	0.89	0.89	2.04	2.04	16.5 K	16.5 K
Weighted Average Shares Outstanding	91.5 M	91.4 M	91.5 M	91.5 M	91.5 M	93.6 M	89.4 M	91.5 M	90.5 M	92.5 M	90.5 M	90.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	91.5 M	9.15 K	9.15 K

All numbers in RUB currency

The income statement is one of the three key financial reports of a company Завод ДИОД (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

How much revenue the company earned
How much it spent on production, personnel, marketing, taxes, etc.
What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features

The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-	2.43 %	$ 254 M	Germany
Pharming Group N.V. PHAR	$ 17.91	-1.0 %	$ 7.59 B	Niderland
Arbutus Biopharma Corporation ABUS	$ 4.78	-0.31 %	$ 793 M	Canada
Aclaris Therapeutics ACRS	$ 3.03	-0.49 %	$ 234 M	USA
InflaRx N.V. IFRX	$ 1.09	-4.82 %	$ 152 M	Germany
Aeglea BioTherapeutics AGLE	-	-	$ 1.01 B	USA
Alpine Immune Sciences ALPN	-	-	$ 2.17 B	USA
AlloVir ALVR	-	4.14 %	$ 49.1 M	USA
Midatech Pharma plc MTP	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	-	-	$ 40.3 B	USA
Biophytis SA BPTS	-	-13.47 %	$ 169 M	France
Aptorum Group Limited APM	$ 1.15	-1.71 %	$ 6.27 M	China
Ampio Pharmaceuticals AMPE	-	-11.43 %	$ 502 K	USA
EyeGate Pharmaceuticals, Inc. EYEG	-	-1.52 %	$ 24.7 M	USA
Applied Molecular Transport AMTI	-	-	$ 10.1 M	USA
Ascendis Pharma A/S ASND	$ 209.39	-1.61 %	$ 5 B	Danmark
Aptevo Therapeutics APVO	$ 0.6	-35.8 %	$ 166 K	USA
Alterity Therapeutics Limited ATHE	$ 3.12	0.81 %	$ 7.51 B	Australia
BioVie BIVI	$ 1.2	-5.51 %	$ 1.77 M	USA
Athersys ATHX	-	3.77 %	$ 22.4 M	USA
Институт стволовых клеток человека ISKJ	-	-	-	Russia
Avenue Therapeutics ATXI	-	-52.27 %	$ 4.45 M	USA
ARCA biopharma ABIO	-	1052.0 %	$ 415 M	USA
AVROBIO AVRO	-	1083.1 %	$ 745 M	USA
Can-Fite BioPharma Ltd. CANF	$ 0.22	24.46 %	$ 479 M	Israel
Acasti Pharma ACST	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	-	-15.15 %	$ 60.3 M	Britain
BioDelivery Sciences International BDSI	-	-4.8 %	$ 255 M	USA
Albireo Pharma ALBO	-	-0.23 %	$ 916 M	USA
BioNTech SE BNTX	$ 94.72	-0.33 %	$ 27.2 B	Germany
Amphastar Pharmaceuticals AMPH	$ 27.09	1.04 %	$ 1.31 B	USA
BeiGene, Ltd. BGNE	-	0.49 %	$ 251 B	Cayman-islands
Anika Therapeutics ANIK	$ 9.6	1.27 %	$ 141 M	USA
Bellicum Pharmaceuticals BLCM	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	-	-	$ 546 M	USA
Arena Pharmaceuticals ARNA	-	-6.81 %	$ 3.04 B	USA
Acer Therapeutics ACER	-	2.71 %	$ 14 M	USA
Calithera Biosciences CALA	-	-10.95 %	$ 876 K	USA
Axon Enterprise AXON	$ 584.81	-1.07 %	$ 44.3 B	USA
Cellectar Biosciences CLRB	$ 2.53	-8.33 %	$ 30.9 M	USA
Ayala Pharmaceuticals AYLA	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	$ 2.44	-3.56 %	$ 15.3 M	USA
AstraZeneca PLC AZN	$ 92.79	0.37 %	$ 96.9 B	Britain
Acorda Therapeutics ACOR	-	-24.86 %	$ 820 K	USA
Catalyst Biosciences CBIO	$ 12.33	-0.29 %	$ 812 M	USA
Brickell Biotech BBI	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	$ 9.1	1.0 %	$ 1.48 B	Britain
Celldex Therapeutics CLDX	$ 26.29	-2.01 %	$ 1.69 M	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	$ 11.07	2.45 %	$ 716 M	USA

Завод ДИОД Income Statement 2007-2025 | DIOD

Annual Income Statement Завод ДИОД

Revenue

Cost Of Revenue

Gross Profit

Gross Profit Ratio

General and Administrative Expenses

Selling And Marketing Expenses

Selling General And Administrative Expenses

Other Expenses

Operating Expenses

Cost And Expenses

Interest Expense

Depreciation And Amortization

EBITDA

EBITDA Ratio

Operating Income

Operating Income Ratio

Income Before Tax

Income Before Tax Ratio

Income Tax Expense

Net Income Ratio

Earnings Per Share, EPS

EPS Diluted

Weighted Average Shares Outstanding